Table 2.
Baseline characteristics
| Control (n = 569) | Olmesartan (n = 578) | P-value | |
|---|---|---|---|
| Age (years) | 65.5 ± 10.1 | 65.8 ± 10.4 | 0.445 |
| Males (%) | 427 (75.2%) | 429 (74.2%) | 0.71 |
| Body weight (kg) | 64.1 ± 12.9 | 63.2 ± 12.7 | 0.297 |
| Height (cm) | 161.0 ± 9.1 | 160.8 ± 9.6 | 0.655 |
| Body mass index (kg/m2) | 24.6 ± 4.1 | 24.2 ± 4.1 | 0.185 |
| NYHA functional class | 0.564 | ||
| II | 530 (93.5%) | 535 (92.6%) | |
| III | 37 (6.5%) | 43 (7.4%) | |
| Baseline cardiovascular disease | |||
| Ischaemic heart disease | 262 (46.1%) | 283 (49%) | 0.337 |
| Dilated cardiomyopathy | 132 (23.2%) | 110 (19%) | 0.081 |
| Diabetes mellitus | 292 (51.4%) | 283 (49%) | 0.408 |
| Haemodynamics and LV function | |||
| Systolic blood pressure (mmHg) | 127.1 ± 18.0 | 128.7 ± 18.2 | 0.081 |
| Diastolic blood pressure (mmHg) | 73.9 ± 11.7 | 74.8 ± 12.2 | 0.311 |
| Heart rate (bpm) | 71.5 ± 14.6 | 71.2 ± 13.8 | 0.808 |
| LVDd (mm) | 54.0 ± 8.7 | 53.3 ± 9.0 | 0.113 |
| LVEF (%) | 53.7 ± 14.5 | 54.5 ± 14.9 | 0.277 |
| ≤40% | 106 (18.8%) | 110 (19.2%) | 0.874 |
| >40 and <50% | 112 (19.9%) | 101 (17.6%) | 0.328 |
| ≥50% | 346 (61.3%) | 363 (63.2%) | 0.510 |
| Laboratory findings | |||
| Haemoglobin (g/dL) | 13.7 ± 1.9 | 13.8 ± 1.7 | 0.279 |
| Blood urea nitrogen (mg/dL) | 18.0 ± 6.9 | 18.3 ± 7.5 | 0.556 |
| Creatinine (mg/dL) | 0.95 ± 0.36 | 0.94 ± 0.33 | 0.956 |
| Albumin (mg/dL) | 4.2 ± 0.4 | 4.2 ± 0.4 | 0.28 |
| LDL-C (mg/dL) | 107.3 ± 30.0 | 108.2 ± 30.8 | 0.775 |
| eGFR (mL/min/1.73 m2) | 70.4 ± 24.4 | 70.0 ± 22.6 | 0.887 |
| BNP (pg/mL) | 78.2 (37.8, 173.0) | 84.2 (36.7, 188.8) | 0.63 |
| Baseline medication | |||
| β-Blocker | 416 (73.2%) | 405 (70.1%) | 0.234 |
| ACEI | 460 (81.0%) | 469 (81.1%) | 0.946 |
| Diuretics | 322 (56.7%) | 328 (56.7%) | 0.984 |
| Thiazides | 22 (3.9%) | 19 (3.3%) | 0.593 |
| Loop diuretics | 296 (52.1%) | 292 (50.5%) | 0.589 |
| Spironolactone | 153 (26.9%) | 152 (26.3%) | 0.807 |
| Calcium-channel blocker | 212 (37.3%) | 222 (38.4%) | 0.705 |
| Statin | 274 (48.2%) | 287 (49.7%) | 0.632 |
NYHA, New York Heart Association; LVDd, left ventricular diastolic dimension; LVEF, left ventricular ejection fraction; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide.